{
    "root": "35a64ceb-88bf-d4ed-e063-6394a90a7799",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TADALAFIL",
    "value": "20250521",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        }
    ],
    "indications": {
        "text": "tadalafil tablets phosphodiesterase 5 ( pde5 ) inhibitor indicated treatment : erectile dysfunction ( ed ) ( 1.1 ) signs symptoms benign prostatic hyperplasia ( bph ) ( 1.2 ) ed signs symptoms bph ( ed/bph ) ( 1.3 ) tadalafil tablets used finasteride initiate bph treatment , recommended 26 weeks ( 1.4 ) .",
        "doid_entities": [
            {
                "text": "erectile dysfunction (DOID:1875)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1875"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "split tadalafil tablets ; entire dose taken .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "tadalafil tablets patients using form organic nitrate contraindicated . tadalafil tablets shown potentiate hypotensive effect nitrates ( 4.1 ) . history known serious hypersensitivity reaction tadalafil tablets adcirca \u00ae ( 4.2 ) . guanylate cyclase ( gc ) stimulators , riociguat ( 4.3 ) .",
    "indications_original": "Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ).",
    "contraindications_original": "Do not split tadalafil tablets; entire dose should be taken.",
    "adverseReactions_original": "Administration of tadalafil tablets to patients using any form of organic nitrate is contraindicated. Tadalafil tablets were shown to potentiate the hypotensive effect of nitrates ( 4.1 ). History of known serious hypersensitivity reaction to tadalafil tablets or ADCIRCA \u00ae ( 4.2 ). Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 ).",
    "drug": [
        {
            "name": "TADALAFIL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_71940"
        }
    ]
}